Robert C. Rose, Ph.D.

Contact Information

Phone Numbers

Research Labs

Our lab pioneered development of virus-like particles (VLPs) for prevention of mucosal human papillomavirus (HPV) disease. Current goals include development of vaccines against dengue and HIV.

Visit Our lab pioneered development of virus-like particles (VLPs) for prevention of mucosal human papillomavirus (HPV) disease. Current goals include development of vaccines against dengue and HIV. Lab Website

Locations

University of Rochester Medical Center
School of Medicine and Dentistry
601 Elmwood Ave, Box 689
Rochester, NY 14642

Faculty Appointments

Professor Emeritus - Department of Medicine , Infectious Diseases (SMD)

Biography

Research

Genital infection with any of several human papillomaviruses (HPVs) is necessary but not sufficient to cause uterine cervical cancer, the second most common female malignancy worldwide. In the late 1980s we established antibody-mediated virus neutralization as a vaccine concept for prevention of genital HPV infections by using authentic virions of a genital HPV type (type 11 or "HPV11") to demonstrate that viral infectivity could be blocked with capsid-specific antibodies. This observation led us to produce non-infectious "virus-like particles" (VLPs) of prevalent genital HPV types associated with either benign genital warts (HPV11) (1) or cervical cancer (HPV16 and HPV18) (3). By comparing HPV11 recombinant VLPs with authentic native genital HPV11 virions, we were able to show that VLPs accurately mimic viral structure and immunological properties. We then formally demonstrated that this approach to vaccine development was valid by showing that antibodies raised against HPV11 L1 VLPs efficiently neutralized authentic HPV11 virus particles (2).Our subsequent evaluations of antibody responses against VLPs derived from three genetically distinct genital HPV types (i.e., types 11, 16 and 18) led us to conclude that antibody-mediated neutralization was genotype-specific, and that multivalent HPV VLP vaccine formulations would be required for the induction of broadly protective immunity against genital HPV disease (3)(4).

We next developed a collaboration with a small biotechnology company (MedImmune, Inc., Gaithersburg, MD), and performed the first-in-humans administration of VLPs in a controlled phase 1 clinical study of VLP safety and tolerability. The results of our study indicated that VLPs are safe and well-tolerated (11). Next, phase 2 and phase 3 clinical studies were performed by GlaxoSmithKline, and by Merck, Sharp & Dohme. Results from those studies demonstrated that VLP vaccines are highly effective for preventing cervical cancer precursor lesions. In June 2006, Gardasil (a tetravalent VLP vaccine formulation made by Merck) was approved by the FDA, and recommended by the CDC's Advisory Committee on Immunization Practices (ACIP) for universal immunization of 11 and 12 year old females. A bivalent formulation developed by Glaxosmithkline is now under FDA review.

More recently our work has involved the development of alternative needle-free methods for VLP administration that we hope will prove to be more suitable for use in developing world regions where most cervical cancer occurs (8, 9, 13). We are also developing chimeric VLP-based vaccines for therapy of established genital HPV disease, or for preventing or treating diseases caused by other viruses including HIV and Dengue.

Credentials

Education

1984
BS | SUNY Geneseo
Biology

1990
MS | Univ Rochester Sch Med/Dent
Microbiology

1994
PhD | Univ Rochester Sch Med/Dent
Virology

Awards

2009
George Eastman Medal for Outstanding Achievement
Sponsor: University of Rochester School of Medicine and Dentistry
Location: Rochester, NY

2007
Health Care Achievement Award
Sponsor: Rochester Business Journal
Location: Rochester, NY

2007
Inspiration Award
Sponsor: James P. Wilmot Cancer Center
Location: University of Rochester, Rochester, NY

2006
Distinguished Inventor of the Year Award
Sponsor: Rochester Intellectual Property Law Association
Location: Rochester, NY

2006
United States Congressional Record
Sponsor: Speech by Honorable Louise Slaughter, D-NY
Location: Washington, D.C.

2005
Davey Memorial Award for Outstanding Cancer Research
Sponsor: James P. Wilmot Cancer Center
Location: University of Rochester, Rochester, NY

1994
Melville A. Hare Distinguished Research Award
Sponsor: Department of Microbiology and Immunology
Location: University of Rochester, Rochester, NY

VIEW ALL

Patents

Patent Title: Transcutaneous Immunization Against Papillomavirus with Papillomavirus Virus-like Particles
Patent #: 7,247,433
Issue Date: Jul 24, 2007
Country: United States
Invented By: Robert C Rose

Patent Title: Transcutaneous Immunization Against Papillomavirus with Papillomavirus Virus-Like Particles
Patent #: 2,457,804
Issue Date: Oct 16, 2012
Country: Canada
Invented By: Robert C Rose

Patent Title: Transcutaneous Immunization Against Papillomavirus with Papillomavirus Virus-Like Particles
Patent #: 2002367977
Issue Date: Oct 02, 2008
Country: Australia
Invented By: Robert C Rose

Patent Title: Transcutaneous Immunization Against Papillomavirus Disease
Patent #: 1425423
Issue Date: Jun 23, 2010
Country: Europe
Invented By: Robert C Rose

Patent Title: Transcutaneous Immunization Against Papillomavirus Disease
Patent #: FR1425423
Issue Date: Jun 23, 2010
Country: France
Invented By: Robert C Rose

Patent Title: Transcutaneous Immunization Against Papillomavirus Disease
Patent #: DE1425423
Issue Date: Jun 23, 2010
Country: Germany
Invented By: Robert C Rose

Patent Title: Transcutaneous Immunization Against Papillomavirus Disease
Patent #: GB1425423
Issue Date: Jun 23, 2010
Country: United Kingdom
Invented By: Robert C Rose

Patent Title: Rapid Diagnostic Chips for Detection of Immune Responses to HPV (Human Papilloma Virus)
Patent #: 8,450,056
Issue Date: May 28, 2013
Country: United States
Invented By: Charles R Mace, Benjamin Locke Miller, Tim R Mosmann, Robert C Rose

Patent Title: Production of Papillomavirus Capsid Protein and Virus-like Particles
Patent #: 0688227
Issue Date: May 25, 2005
Country: Europe
Invented By: William Bonnez, Richard Reichman, Robert C Rose

Patent Title: Production of Papillomavirus Capsid Protein and Virus-Like Particles
Patent #: 5386392
Issue Date: Oct 11, 2013
Country: Japan
Invented By: William Bonnez, Richard Reichman, Robert C Rose

Patent Title: Production of Papillomavirus Capsid Protein and Virus-Like Particles
Patent #: 5306251
Issue Date: Jul 05, 2013
Country: Japan
Invented By: William Bonnez, Richard Reichman, Robert C Rose

Patent Title: Production of Papillomavirus Capsid Protein and Virus-Like Particles
Patent #: 8,062,642
Issue Date: Nov 22, 2011
Country: United States
Invented By: William Bonnez, Richard Reichman, Robert C Rose

Patent Title: Production of Human Papillomavirus Virus Capsid Protein and Virus-Like Particles
Patent #: 688759
Issue Date: Oct 11, 2007
Country: Australia
Invented By: William Bonnez, Richard Reichman, Robert C Rose

Patent Title: Production of Human Papillomavirus HBV-11 Capsid Protein L1 and Virus-Like Particles
Patent #: HK1082196
Issue Date: Aug 05, 2011
Country: Hong Kong
Invented By: William Bonnez, Richard Reichman, Robert C Rose

Patent Title: Production of Human Papillomavirus HBV-11 Capsid Protein L1 and Virus-Like Particles
Patent #: 1588713
Issue Date: Dec 22, 2010
Country: Europe
Invented By: William Bonnez, Richard Reichman, Robert C Rose

Patent Title: Production of Human Papillomavirus Capsid Protein and Virus-like Particles
Patent #: 4486075
Issue Date: Apr 02, 2010
Country: Japan
Invented By: William Bonnez, Richard Reichman, Robert C Rose

Patent Title: Production of Human Papillomavirus Capsid Protein and Virus-Like Particles
Patent #: HK1618888
Issue Date: May 01, 2011
Country: Hong Kong
Invented By: William Bonnez, Richard Reichman, Robert C Rose

Patent Title: Production of Human Papillomavirus Capsid Protein and Virus-Like Particles
Patent #: 1618888
Issue Date: Jan 05, 2011
Country: Europe
Invented By: William Bonnez, Richard Reichman, Robert C Rose

Patent Title: Production of Human Papillomavirus Capsid Protein and Virus-Like Particles
Patent #: BE1618888
Issue Date: Jan 05, 2011
Country: Belgium
Invented By: William Bonnez, Richard Reichman, Robert C Rose

Patent Title: Production of Human Papillomavirus Capsid Protein and Virus-Like Particles
Patent #: DK1618888
Issue Date: Jan 05, 2011
Country: Denmark
Invented By: William Bonnez, Richard Reichman, Robert C Rose

Patent Title: Production of Human Papillomavirus Capsid Protein and Virus-Like Particles
Patent #: FR1618888
Issue Date: Jan 05, 2011
Country: France
Invented By: William Bonnez, Richard Reichman, Robert C Rose

Patent Title: Production of Human Papillomavirus Capsid Protein and Virus-Like Particles
Patent #: DE69435332.9
Issue Date: Jan 05, 2011
Country: Germany
Invented By: William Bonnez, Richard Reichman, Robert C Rose

Patent Title: Production of Human Papillomavirus Capsid Protein and Virus-Like Particles
Patent #: GR20110400515
Issue Date: Jan 05, 2011
Country: Greece
Invented By: William Bonnez, Richard Reichman, Robert C Rose

Patent Title: Production of Human Papillomavirus Capsid Protein and Virus-Like Particles
Patent #: IE1618888
Issue Date: Jan 05, 2011
Country: Ireland
Invented By: William Bonnez, Richard Reichman, Robert C Rose

Patent Title: Production of Human Papillomavirus Capsid Protein and Virus-Like Particles
Patent #: IT68306 BE/2011
Issue Date: Jan 05, 2011
Country: Italy
Invented By: William Bonnez, Richard Reichman, Robert C Rose

Patent Title: Production of Human Papillomavirus Capsid Protein and Virus-Like Particles
Patent #: LU1618888
Issue Date: Jan 05, 2011
Country: Luxembourg
Invented By: William Bonnez, Richard Reichman, Robert C Rose

Patent Title: Production of Human Papillomavirus Capsid Protein and Virus-Like Particles
Patent #: MC1618888
Issue Date: Jan 05, 2011
Country: Monaco
Invented By: William Bonnez, Richard Reichman, Robert C Rose

Patent Title: Production of Human Papillomavirus Capsid Protein and Virus-Like Particles
Patent #: PT1618888
Issue Date: Jan 05, 2011
Country: Portugal
Invented By: William Bonnez, Richard Reichman, Robert C Rose

Patent Title: Production of Human Papillomavirus Capsid Protein and Virus-Like Particles
Patent #: CH1618888
Issue Date: Jan 05, 2011
Country: Switzerland/Liechtenstein
Invented By: William Bonnez, Richard Reichman, Robert C Rose

Patent Title: Production of Human Papillomavirus Capsid Protein and Virus-Like Particles
Patent #: NL1618888
Issue Date: Jan 05, 2011
Country: Netherlands
Invented By: William Bonnez, Richard Reichman, Robert C Rose

Patent Title: Production of Human Papillomavirus Capsid Protein and Virus-Like Particles
Patent #: GB1618888
Issue Date: Jan 05, 2011
Country: United Kingdom
Invented By: William Bonnez, Richard Reichman, Robert C Rose

Patent Title: Production of Human Papillomavirus Capsid Protein and Virus-Like Particles
Patent #: ES1618888
Issue Date: Jan 05, 2011
Country: Spain
Invented By: William Bonnez, Richard Reichman, Robert C Rose

Patent Title: Production of Human Papillomavirus Capsid Protein and Virus-Like Particles
Patent #: SE1618888
Issue Date: Jan 05, 2011
Country: Sweden
Invented By: William Bonnez, Richard Reichman, Robert C Rose

Patent Title: Production of Human Papillomavirus Capsid Protein and Virus-Like Particles
Patent #: AT1618888
Issue Date: Jan 05, 2011
Country: Austria
Invented By: William Bonnez, Richard Reichman, Robert C Rose

Patent Title: Production of Human Papillomavirus Capsid Protein and Virus-Like Particles
Patent #: BE1588713
Issue Date: Dec 22, 2010
Country: Belgium
Invented By: William Bonnez, Richard Reichman, Robert C Rose

Patent Title: Production of Human Papillomavirus Capsid Protein and Virus-Like Particles
Patent #: FR05075889.5
Issue Date: Dec 22, 2010
Country: France
Invented By: William Bonnez, Richard Reichman, Robert C Rose

Patent Title: Production of Human Papillomavirus Capsid Protein and Virus-Like Particles
Patent #: DE69435331.0
Issue Date: Dec 22, 2010
Country: Germany
Invented By: William Bonnez, Richard Reichman, Robert C Rose

Patent Title: Production of Human Papillomavirus Capsid Protein and Virus-Like Particles
Patent #: IT68034 BE/2011
Issue Date: Dec 22, 2010
Country: Italy
Invented By: William Bonnez, Richard Reichman, Robert C Rose

Patent Title: Production of Human Papillomavirus Capsid Protein and Virus-Like Particles
Patent #: ES1588713
Issue Date: Dec 22, 2010
Country: Spain
Invented By: William Bonnez, Richard Reichman, Robert C Rose

Patent Title: Production of Human Papillomavirus Capsid Protein and Virus-Like Particles
Patent #: GB05075889.5
Issue Date: Dec 22, 2010
Country: United Kingdom
Invented By: William Bonnez, Richard Reichman, Robert C Rose

Patent Title: Production of Human Papillomavirus Capsid Protein and Virus-Like Particles
Patent #: 2007201006
Issue Date: Nov 28, 2010
Country: Australia
Invented By: William Bonnez, Richard Reichman, Robert C Rose

Patent Title: Production of Human Papillomavirus Capsid Protein and Virus-Like Particles
Patent #:
Issue Date: Nov 25, 2010
Country: Australia
Invented By: William Bonnez, Richard Reichman, Robert C Rose

Patent Title: Papillomavirus Capsid Protein and Virus-like Particles
Patent #: 2,157,932
Issue Date: Oct 11, 2011
Country: Canada
Invented By: William Bonnez, Richard Reichman, Robert C Rose

Patent Title: Oral Immunization with Papillomavirus Virus-Like Particles
Patent #: 6,153,201
Issue Date: Nov 28, 2000
Country: United States
Invented By: Robert C Rose, Edward Rybicki, Anna-Lise Williamson

Patent Title: Method of Determining Immune Enhancement of Virus Infectivity using FC Receptor-Transfected Cell Lines
Patent #: 8,592,163
Issue Date: Nov 26, 2013
Country: United States
Invented By: Xia Jin, W.W. Shanaka I Rodrigo, Robert C Rose, Jacob J Schlesinger

Patent Title: Method of Determining Immune Enhancement of Virus Infectivity Using Fc Receptor-Transfected Cell Lines
Patent #: 2006252637
Issue Date: Jan 05, 2012
Country: Australia
Invented By: W.W. Shanaka I Rodrigo, Robert C Rose, Jacob J Schlesinger

Patent Title: Homogeneous Human Papillomavirus Capsomere Containing Compositions, Methods for Manufacture, and Use Thereof as Diagnostic, Prophylactic, or Therapeutic Agents
Patent #: 2,295,316
Issue Date: Jun 26, 2007
Country: Canada
Invented By: Robert L Garcea, Michael P McCarthy, Robert C Rose, JoAnn A Suzich

Patent Title: Homogeneous Human Papillomavirus Capsomere Containing Compositions, Methods for Manufacture, and Use Thereof as Diagnostic, Prophylactic, or Therapeutic Agents
Patent #: 755679
Issue Date: Jan 25, 1999
Country: Australia
Invented By: Robert L Garcea, Michael P McCarthy, Robert C Rose, JoAnn A Suzich

Patent Title: Homogeneous Human Papillomavirus Capsomere Containing Compositions, Methods for Manufacture, and Use Thereof as Diagnostic, Prophylactic or Therapeutics Agents
Patent #: 6,165,471
Issue Date: Dec 26, 2000
Country: United States
Invented By: Robert L Garcea, Michael P McCarthy, Robert C Rose, JoAnn A Suzich

Patent Title: Combined Human Papillomavirus VLP/Gene Delivery System and Use Thereof As a Vaccine for Prophylaxis and Immunotherapy of Infectious Diseases and Tumors
Patent #: 8,778,351
Issue Date: Jul 15, 2014
Country: United States
Invented By: YoungEun Ellen Lee Son, Christine Malboeuf, Robert C Rose

Patent Title: Arrayed Detector System for Measurement of Anti-Viral Immune Response
Patent #: 9,034,638
Issue Date: May 19, 2015
Country: United States
Invented By: Charles R Mace, Benjamin Locke Miller, Tim R Mosmann, Robert C Rose

VIEW ALL

Publications

Journal Articles

11/25/2009
Rodrigo WW, Block OK, Lane C, Sukupolvi-Petty S, Goncalvez AP, Johnson S, Diamond MS, Lai CJ, Rose RC, Jin X, Schlesinger JJ. "Dengue virus neutralization is modulated by IgG antibody subclass and Fcgamma receptor subtype." Virology.. 2009 Nov 25; 394(2):175-82. Epub 2009 Oct 14.

6/18/2009
Murata Y, Lightfoote PM, Rose RC, Walsh EE. "Antigenic presentation of heterologous epitopes engineered into the outer surface-exposed helix 4 loop region of human papillomavirus L1 capsomeres." Virology journal.. 2009 Jun 18; 6:81. Epub 2009 Jun 18.

2/2009
Rodrigo WW, Alcena DC, Kou Z, Kochel TJ, Porter KR, Comach G, Rose RC, Jin X, Schlesinger JJ. "Difference between the abilities of human Fcgamma receptor-expressing CV-1 cells to neutralize American and Asian genotypes of dengue virus 2." Clinical and vaccine immunology : CVI.. 2009 Feb; 16(2):285-7. Epub 2008 Nov 26.

Books & Chapters

2002
Chapter Title: Human Papillomavirus Immunology and Vaccine Development
Book Title: Perspectives in Medical Virology
Author List: Rose, R.C.
Edited By: D.J. McCance
Published By: Elsevier 2002 in Amsterdam

1997
Chapter Title: Human Papillomavirus Infections
Book Title: Antiviral Agents and Human Viral Diseases
Author List: Rose, R.C. Bonnez, W. Reichman, R.C.
Edited By: G.J. Galasso, R.C. Whitley, and T.C. Merigan
Published By: Raven Press 1997 in New York

VIEW ALL PUBLICATIONS